We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
- Authors
Moeko Ochiai; Eiichi Tanaka; Eri Sato; Eisuke Inoue; Mai Abe; Kumiko Saka; Eri Sugano; Naohiro Sugitani; Yoko Higuchi; Rei Yamaguchi; Naoki Sugimoto; Katsunori Ikari; Ayako Nakajima; Hisashi Yamanaka; Masayoshi Harigai
- Abstract
Objectives: To analyze the proportion of successful biological disease-modifying antirheumatic drugs (bDMARDs) discontinuation and related factors in patients with rheumatoid arthritis (RA) in clinical settings. Methods: Among 1775 RA patients who started bDMARDs between 2003 and 2012, 43 patients with DAS28-ESR <3.2 at the time of bDMARD discontinuation were extracted. Patients were divided into two groups (bio-free success: BS and bio-free failure: BF groups) based on bDMARD usage and disease activity 1 year after discontinuation. We evaluated the proportion of bio-free success and assessed factors related to bio-free success. Results: Twenty-five patients (58.1%: BS group) maintained discontinuation of bDMARDs and DAS28- ESR <3.2 at 1 year after discontinuation. The median DAS28-ESR at bDMARD initiation was lower in the BS group than in the BF group (3.95 vs 5.04; p=.04). The BS group experienced a larger decrease in average glucocorticoid (GC) dose during bDMARD use than the BF group (-3.0 mg/day vs 0 mg/ day; p=.01). Conclusion: bDMARDs were discontinued without flare up of RA in 58.1% of patients with RA in clinical settings. A lower DAS28-ESR at initiation and reduction of GC dose before discontinuation of bDMARD were important factors associated with bio-free success.
- Subjects
ANTIRHEUMATIC agents; RHEUMATOID arthritis; GLUCOCORTICOIDS; PATIENTS; ARTHRITIS
- Publication
Modern Rheumatology, 2021, Vol 31, Issue 4, p790
- ISSN
1439-7595
- Publication type
Article
- DOI
10.1080/14397595.2021.1883252